US2015137428A1PendingUtilityA1
Methods of stabilizing molecular weight of polymer stents after sterilization
Assignee: ABBOTT CARDIOVASCULAR SYSTEMSPriority: May 9, 2011Filed: Jan 14, 2015Published: May 21, 2015
Est. expiryMay 9, 2031(~4.8 yrs left)· nominal 20-yr term from priority
A61F 2240/001A61F 2/82B65B 55/16A61L 2/087A61L 2/082A61L 2/081A61F 2/0095B29C 71/009B29C 2035/0877B29C 71/04
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods of stabilizing the molecular weight of polymer stents scaffolds after E-beam sterilization are disclosed. The molecular weight of the polymer of the irradiated scaffolds is stabilized through exposure to gas containing oxygen.
Claims
exact text as granted — not AI-modified1 - 3 . (canceled)
4 . A method of making a stent, comprising:
providing a polymeric stent scaffolding comprising a polymer; selecting a final number average molecular weight (Mn) of the polymer of the scaffolding; irradiating the scaffolding with E-beam radiation for sterilization in an inert gas environment, wherein the polymer of the scaffolding has an initial Mn after the irradiation; allowing the Mn of the irradiated scaffolding to increase from the initial Mn to the final Mn in the inert gas environment; and exposing the scaffolding to an oxygen-containing gas to stabilize the Mn of the scaffolding at the final Mn.
5 . The method of claim 4 , further comprising storing the stabilized scaffolding in an inert gas environment.
6 . The method of claim 4 , wherein the oxygen-containing gas is air.
7 . The method of claim 4 , wherein the scaffolding polymer is poly(L-lactide) (PLLA).
8 . The method of claim 4 , wherein the scaffolding polymer is a lactide-based polymer.
9 . The method of claim 4 , wherein the initial Mn is 70 to 80 kDa and the final Mn is 80 to 130 kDa.
10 . The method of claim 4 , wherein a free radical concentration decays to less than 5×10 7 DI/mg after stabilizing the Mn of the scaffolding.
11 . The method of claim 10 , wherein the free radical concentration decays to less than 5×10 7 DI/mg in less than 2 days after exposing the scaffolding to the oxygen-containing gas.
12 . The method of claim 4 , wherein an oxygen content of the oxygen-containing gas is 5 to 10%.
13 . The method of claim 4 , wherein an oxygen content of the oxygen-containing gas is 10 to 20%.
14 . A method of making a stent comprising:
providing a polymeric stent scaffolding comprising a polymer; sterilizing the scaffolding with radiation; allowing the molecular weight of the sterilized scaffold to increase for a period of time after sterilization; and stopping the molecular weight increase through exposure of the scaffolding to an oxygen-containing gas to stabilize the polymer at a desired number average molecular weight (Mn).
15 . The method of claim 14 , further comprising storing the stabilized scaffolding in an inert gas environment.
16 . The method of claim 14 , wherein the oxygen-containing gas is air.
17 . The method of claim 14 , wherein the scaffolding polymer is a lactide-based polymer.
18 . The method of claim 14 , wherein the molecular weight is allowed to increase from an initial Mn of 70 to 80 kDa to a stabilized Mn of 80 to 130 kDa.
19 . The method of claim 14 , wherein a free radical concentration decays to less than 5×10 7 DI/mg after stabilizing the Mn of the scaffolding.
20 . The method of claim 19 , wherein the free radical concentration decays to less than 5×10 7 DI/mg in less than 2 days after exposing the scaffolding to the oxygen-containing gas.Join the waitlist — get patent alerts
Track US2015137428A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.